



OPEN ACCESS

EDITED AND REVIEWED BY
Alfredo Vannacci,
University of Florence, Italy

*CORRESPONDENCE

Song Liang,
✉ song11963@163.com
Dan Sun,
✉ bloveriver@163.com

[†]These authors have contributed equally to this work

RECEIVED 17 September 2023
ACCEPTED 19 September 2023
PUBLISHED 29 September 2023

CITATION

Yi J-Q, Huang S, Wu M-J, Ma J-H, Huang L-J, Liang S and Sun D (2023), Corrigendum: Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy. *Front. Pharmacol.* 14:1295784. doi: 10.3389/fphar.2023.1295784

COPYRIGHT

© 2023 Yi, Huang, Wu, Ma, Huang, Liang and Sun. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy

Jia-Qin Yi^{1†}, Sheng Huang^{1†}, Miao-Juan Wu¹, Jie-Hui Ma¹, Li-Juan Huang¹, Song Liang^{2*} and Dan Sun^{1*}

¹Department of Neurology, Wuhan Children's Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ²Department of Pediatric Rehabilitation, Hubei the Third People's Hospital, Wuhan, China

KEYWORDS

perampanel, oxcarbazepine, newly diagnosed focal epilepsy, monotherapy, anti-seizure medications

A Corrigendum on

Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy

by Yi J-Q, Huang S, Wu M-J, Ma J-H, Huang L-J, Liang S and Sun D (2023). *Front. Pharmacol.* 14:1189058. doi: 10.3389/fphar.2023.1189058

In the published article, there was an error in [Figure 2](#) as published. The 3-month seizure freedom rate in OXC group should be 80.7% in the original figure. The 6-month seizure freedom rate in OXC group should be 43/55. The corrected [Figure 2](#) and its caption appear below.

In the published article, there was also an error in the text. The 6-month seizure freedom rate in OXC group should be 43/55.

A correction has been made to **3 Result**, 3.2 Primary endpoint, paragraph 1. This sentence previously stated:

“In the PPS, 78.1% (50/64, 95% CI: 66.0%–87.5%) of children in the PER group and 78.2% (43/56) in the OXC group were seizure-free at 6 months.”

The corrected sentence appears below:

“In the PPS, 78.1% (50/64, 95% CI: 66.0%–87.5%) of children in the PER group and 78.2% (43/55) in the OXC group were seizure-free at 6 months.”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 2 Seizure-response status and seizure-free status on PER/OXC monotherapy. (A) OP3; (B) OP6; and (C) OP12. Seizure free: seizure freedom; Sz reduce ≥75%: seizure reduction ≥75%; Sz reduce ≥50%: seizure reduction ≥50%.